Objective We reviewed the current literature regarding antiretroviral (ARV)-sparing therapy
strategies to determine whether these novel regimens can be considered appropriate …

Lipodystrophy syndromes comprise a group of rare, heterogeneous disorders characterized
by progressive loss of fat tissue, mainly from subcutaneous compartment and occasionally …

Background Little is known about the applicability of dual treatments based on integrase
inhibitors. We explored the combination of lamivudine+ dolutegravir as an option when …

Dual treatments could help clinicians to avoid drawbacks and toxicities due to the
nucleosidic backbone, while maintaining the efficacy and convenience of robust …

Background. Nucleoside reverse-transcriptase inhibitor (NRTI)-related mitochondrial toxicity
has been suggested as a key factor in the induction of antiretroviral-related lipoatrophy. This …

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of compounds
that inhibit HIV Type 1 reverse transcriptase. Although possessing a common mechanism of …

Background: Lopinavir is a protease inhibitor with high specificity for HIV-1 protease
formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) …

The first cases of AIDS in Spain were reported in 1982. Since then over 85,000 persons with
AIDS have been cumulated, with 60,000 deaths. Current estimates for people living with HIV …

Nucleoside reverse transcriptase inhibitor (NRTI)-and protease inhibitor (PI)-sparing
antiretroviral regimens may be useful in selected human immune deficiency virus (HIV) …

Highly active antiretroviral therapies (HAART) provide sustained viral control in most
patients, but many of these regimens are restricted by complex dosing, drug–drug …